Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,733 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,059 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02180867 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | completed | Phase 2 / Phase 3 | 140 | National Cancer Institute (NCI)NIH | 3 | Jun 17, 2026 | clinicaltrials |
| NCT07219238 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | recruiting | Phase 2 / Phase 3 | 175 | GE HealthcareINDUSTRY |
| 2 |
| Jun 17, 2026 |
| clinicaltrials |
| NCT07596290 | Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC(RADICAL) | not yet recruiting | Phase 2 / Phase 3 | 342 | Beijing Friendship HospitalOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT07653451 | Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer(ESCC-PT) | not yet recruiting | Phase 2 / Phase 3 | 90 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT06642844 | Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment(PHARBEVACOL) | recruiting | Phase 3 | 244 | University Hospital, ToursOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT02945033 | Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk(ASPIK French) | active not recruiting | Phase 3 | 264 | University Hospital, RouenOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06091748 | Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors | completed | Phase 3 | 69 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04635423 | Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064) | completed | Phase 3 | 1,059 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05593458 | Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1(TACTIC) | recruiting | Phase 3 | 190 | Zhejiang UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06446557 | De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer(DIAMOND) | not yet recruiting | Phase 3 | 408 | University Hospital, RouenOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06900543 | Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere(CHEERS) | active not recruiting | Phase 3 | 108 | Chengdu New Radiomedicine Technology Co. LTD.INDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07188025 | ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer(REACT) | recruiting | Phase 3 | 103 | Erasmus Medical CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT02562755 | Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone(PHOCUS) | completed | Phase 3 | 459 | SillaJen, Inc.INDUSTRY | 16 | Jun 8, 2026 | clinicaltrials |
| NCT06783491 | Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer(FOXHIPECT4) | recruiting | Phase 3 | 1,083 | Maimónides Biomedical Research Institute of CórdobaOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07632118 | Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery | recruiting | Phase 3 | 288 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03303495 | A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | recruiting | Phase 3 | 280 | Sun Yat-sen UniversityOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06504732 | To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer | recruiting | Phase 2 / Phase 3 | 574 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07076121 | A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | active not recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 36 | Jun 3, 2026 | clinicaltrials |
| NCT01196390 | Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer | completed | Phase 3 | 203 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04513418 | Effects of Preoperative Enteral Immunonutrition for Esophageal Cancer Patients Given Neoadjuvant Chemoradiotherapy(POINT) | active not recruiting | Phase 3 | 244 | Hecheng Li M.D., Ph.DOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06625320 | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)(RASolute 302) | active not recruiting | Phase 3 | 500 | Revolution Medicines, Inc.INDUSTRY | 7 | Jun 2, 2026 | clinicaltrials |
| NCT06914011 | Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma(MRD2START) | not yet recruiting | Phase 3 | 172 | Asan Medical CenterOTHER | 0 | Jun 2, 2026 | clinicaltrials |
| NCT07621601 | A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) | not yet recruiting | Phase 3 | 494 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Jun 2, 2026 | clinicaltrials |
| NCT00002968 | Edrecolomab in Treating Patients With Stage II Colon Cancer | completed | Phase 3 | 2,100 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04704934 | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) | active not recruiting | Phase 3 | 490 | Daiichi SankyoINDUSTRY | 24 | May 27, 2026 | clinicaltrials |
| NCT05052801 | Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression(FORTITUDE-101) | completed | Phase 3 | 547 | AmgenINDUSTRY | 37 | May 27, 2026 | clinicaltrials |
| NCT05064059 | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) | completed | Phase 3 | 441 | Merck Sharp & Dohme LLCINDUSTRY | 21 | May 26, 2026 | clinicaltrials |
| NCT07284394 | Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease(PACHA-02) | not yet recruiting | Phase 3 | 272 | UNICANCEROTHER | 0 | May 26, 2026 | clinicaltrials |
| NCT02572141 | FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)(OPTICAL) | active not recruiting | Phase 3 | 738 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04230187 | Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer(TRIBE-C) | active not recruiting | Phase 3 | 528 | Yanhong DengOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05239741 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) | active not recruiting | Phase 3 | 100 | Merck Sharp & Dohme LLCINDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT06998940 | Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | recruiting | Phase 3 | 94 | SWOG Cancer Research NetworkNETWORK | 1 | May 22, 2026 | clinicaltrials |
| NCT07462143 | A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 80 | RemeGen Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT07594340 | HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven) | recruiting | Phase 3 | 300 | Binkui LiOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07603349 | Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 / Phase 3 | 405 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06768164 | Quality of Life After Billroth II or Roux-en-Y for Gastric Cancer(BYQoL-GC) | recruiting | Phase 3 | 250 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07598318 | Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations | not yet recruiting | Phase 2 / Phase 3 | 164 | Sir Run Run Shaw HospitalOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT01150045 | Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery | completed | Phase 3 | 2,527 | Alliance for Clinical Trials in OncologyOTHER | 3 | May 19, 2026 | clinicaltrials |
| NCT05884255 | An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. | recruiting | Phase 3 | 220 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07595276 | Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status. | not yet recruiting | Phase 3 | 608 | Taizhou Mabtech Pharmaceutical Co.,LtdINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT04927780 | Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer(PREOPANC-3) | active not recruiting | Phase 3 | 378 | Erasmus Medical CenterOTHER | 2 | May 15, 2026 | clinicaltrials |
| NCT07138846 | A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer | not yet recruiting | Phase 3 | 231 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07591493 | Adjuvant Trial in Pancreatic Neuroendocrine Tumors(ADJUPANET) | not yet recruiting | Phase 3 | 300 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT02514278 | Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy(GRECCAR12) | completed | Phase 3 | 218 | University Hospital, BordeauxOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05652894 | A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer | active not recruiting | Phase 3 | 190 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07241715 | Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE)(CONVERGENCE) | active not recruiting | Phase 2 / Phase 3 | 300 | National University Hospital, SingaporeOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03017326 | Paediatric Hepatic International Tumour Trial(PHITT) | active not recruiting | Phase 3 | 450 | University of BirminghamOTHER | 14 | May 13, 2026 | clinicaltrials |
| NCT04550260 | Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC(KUNLUN) | active not recruiting | Phase 3 | 640 | AstraZenecaINDUSTRY | 16 | May 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 17, 2026source: clinicaltrials